Social pressure
Conform or be excluded.
Social pressure is one of the least visible but most effective tools of the gender movement. It doesn’t work through laws or lawsuits, but through one’s immediate social environment: friends, colleagues, family, and online communities. Those who don’t participate—those who refuse to go along with the language, ideology, or rituals—are stigmatized, ignored, or actively excluded.
Young people are particularly vulnerable to these dynamics. In classrooms, on social media, and among friends, accepting gender ideology has become a social signal. Anyone who expresses doubts risks being labeled “transphobic” or “bigoted”—labels that can have devastating social consequences in peer groups. This creates an environment in which compliance is not voluntary but enforced by fear of exclusion.
Identity politics as group cohesion
Gender ideology functions as an identity marker for a social group. Agreement is the ticket in; doubt is betrayal. This makes it an extraordinarily effective social glue, but also a dangerous one: group dynamics replace individual thinking, and outside criticism strengthens cohesion rather than undermining it. Thus, ideological positions become more radical rather than more nuanced as external pressure increases.
Parents report that their children suddenly adopt a different gender identity after short periods of intensive social media use or exposure to certain peer groups. The social context—the idea that this is “normal” or even admirable—plays a role here that is difficult to separate from underlying individual psychology.
The Right to Say No
A society that calls itself tolerant must make room for people who disagree. Not because dissenting opinions are always right, but because forcing agreement is not tolerance—it is conformism. The LGBTQ+ movement, which claims to champion the freedom of minorities, is creating a new minority: people who disagree and are punished for it.
What the international reevaluation shows
The theme of social pressure is not separate from the broader medical reevaluation. The Cass Review (2024) in the United Kingdom led to a de facto halt on puberty blockers within NHS England. SBU and Karolinska in Sweden withdrew their support for medical transition in minors outside of a research context starting in 2022. Finland (COHERE, 2020) and Norway (UKOM, 2023) followed suit. NICE (2020) classified the evidence base for puberty blockers and cross-sex hormones as “very low certainty.”
The Netherlands is lagging behind. The Dutch Protocol—once touted as an international model—is being abandoned elsewhere. The data on which it is based do not come from randomized trials, but from observational studies with cohorts that are not generalizable to the current referral population.
How the discussion is being stifled
Amid social pressure, the gender-affirming model is defended with moral pressure and scientific claims that do not hold up to scrutiny. Anyone who refers to the Cass Review or the Scandinavian shift is not given a rebuttal but labeled as transphobic. The WPATH Files (2024) showed that even within WPATH there was uncertainty regarding informed consent for minors.
Parents who come forward with concerns are dismissed as troublemakers. Clinicians who advocate for caution face internal complaints and public campaigns. The result: only one side of the story remains heard.
International Reconsideration
In recent years, various national health authorities have distanced themselves from the gender-affirming model for minors. The common denominator: evidence of lasting benefits is lacking, while the risks are real.
Cass Review (2024). Review commissioned by NHS England, conducted by Hilary Cass. Conclusion: the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England ceased the routine prescribing of puberty blockers outside of clinical trials.
SBU — Sweden (2022). The Swedish Agency for Health Technology Assessment (SBU) and Karolinska University Hospital discontinued the use of puberty blockers and hormones for minors outside of clinical trials. Reason: lack of evidence for effectiveness and safety.
NICE — United Kingdom (2020). Two NICE evidence reviews (puberty blockers and cross-sex hormones) classified the evidence base as very low certainty. None of the studies identified met modern methodological standards.
COHERE — Finland (2020). The Finnish Council for Choices in Health Care revised the protocol: psychotherapy as first-line treatment, medical transition for minors only in exceptional cases and within a research setting.
UKOM — Norway (2023). The Norwegian UKOM classified transgender care for minors as experimental; existing protocols do not meet the requirements for evidence-based care.
WPATH Files (2024). Internal discussions among WPATH clinicians acknowledge that informed consent with minors is problematic and that serious side effects (bone density, fertility, cognitive development) are not adequately explained.